A Phase 2 interventional study of REGN2477 and Matching placebo in Fibrodysplasia Ossificans Progressiva, sponsored by Regeneron Pharmaceuticals. Completed at 11 sites in 8 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2022-12-02.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Myositis Ossificans with a site in United States — 4 open to participants now, 6 under way, 2 of them phase 3. Myositis Ossificans · United States.
Among the 19 studies in Myositis Ossificans with a site in United States, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2018, is one of 6 in phase 2, and was the 7th registered.
24 studies on the registry are indexed under Myositis Ossificans; 5 are open to participants now.
Browse Myositis Ossificans studies →4 of the 19 studies in Myositis Ossificans with a site in United States are open now. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 6–30
Ipsen · Sites in United States, Canada
Ages 8+
Incyte Corporation · Sites in United States, Argentina, Australia and 14 more countries
Ages 2–99
The International FOP Association · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 4 Myositis Ossificans studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; 4 take children under 18; none take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 4
First in 2013; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 44 is close to the median of 48 across 16 interventional studies indexed under Myositis Ossificans.
Median enrollment 60 across the 12 interventional studies, 114 across the 7 observational. Of the 13 that completed or were terminated, 6 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 19 have an industry lead sponsor. The 8 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 5 studies filed under Myositis Ossificans — fewer than ten, so there is no comparison to draw.
2 of the studies in Myositis Ossificans with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05090891Incyte CorporationTo Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva | 2027-07-30 |
| NCT06724562University of California, San FranciscoIL1 Inhibition in FOP | 2027-11-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 19 studies in Myositis Ossificans with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a three period study design consisting of a 6-month, randomized, double-blind placebo-controlled treatment (period 1) followed by a 6-month, open-label treatment (period 2) and a follow-up treatment period (period 3).
Primary safety objective of the study is to assess the safety and tolerability of REGN2477 in male and female patients with fibrodysplasia ossificans progressiva (FOP).
Primary efficacy objective of the study is to assess the effect of REGN2477 versus placebo on the change from baseline in heterotopic ossification (HO) in patients with FOP, as determined by 18-NaF uptake in HO lesions by positron emission tomography (PET) and in total volume of HO lesions by computed tomography (CT).
Key Secondary objectives are:
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: REGN2477
Drug: Matching placebo
Pharmaceutical form: liquid product for injection/infusion; Route of administration: Intravenous (IV); Administered during treatment periods 1 and 2.
Pharmaceutical form: Liquid product for injection/infusion; Route of administration: Intravenous (IV); Administered during treatment period 1 only.
Period 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
Treatment-emergent adverse events (TEAEs) are adverse events not present at baseline or represent the exacerbation of a pre-existing condition during the on-treatment period. A serious TEAE was defined as any untoward medical occurrence that resulted in any of following outcomes not present at baseline or represent the exacerbation of a pre-existing condition during the on-treatment period: death, life-threatening, required initial/prolonged in-participant hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect/considered as medically important event. Number of participants with TEAEs and Serious TEAEs are reported.
Time frame: Up to Week 28
Period 1: Number of Participants With TEAEs by Severity
Severity of TEAEs were graded as follows: Mild: Does not interfere in a significant manner with the participant's normal functioning level. It may be an annoyance. Prescription drugs are not ordinarily needed for relief of symptoms but may be given because of personality of the participants. Moderate: Produces some impairment of functioning but is not hazardous to health. It was uncomfortable or an embarrassment. Treatment for symptom may be needed. Severe: Produces significant impairment of functioning or incapacitation and was a definite hazard to the participant's health. Treatment for symptom may be given and/or participants hospitalized. Number of participants with TEAEs by severity is reported.
Time frame: Up to Week 28
Period 1: Time-Weighted Average (Standardized Area Under the Curve [AUC]) of the Percent Change From Baseline in Total Lesion Activity by Fluorine-18-labeled Sodium Fluoride (18^F-NaF) Positron Emission Tomography (PET) at Week 28 (AHO)
18\^F-NaF PET is used to assess lesion and disease activity. Time-weighted average (standardized area under the curve \[AUC\]) of the percent change from baseline in total lesion activity by 18\^F-NaF PET up to Week 28 in AHO analysis set is reported.
Time frame: Baseline and Week 28
Period 1: Percent Change From Baseline in the Total Volume of HO Lesions as Assessed by Computed Tomography (CT) at Week 28 (AHO)
CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Percent change from baseline in the total volume of HO lesions as assessed by CT during Period 1 at Week 28 is reported.
Time frame: Week 28
Period 2: Number of New HO Lesions as Assessed by CT at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)
CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. HO detectable by CT that developed after baseline are referred to as "new HO lesions." Number of new HO lesions as assessed by CT at Week 56 relative to Week 28 scan is reported.
Time frame: Week 28, Week 56
Period 1: Time-weighted Average (Standardized AUC) of the Percent Change From Baseline in Total Lesion Activity Assessed by 18^F-NaF PET at Week 28 (AHOC)
18\^F-NaF PET is used to assess lesion and disease activity. Time-weighted average (Standardized AUC) of the percent change from baseline in total lesion activity as assessed by 18\^F-NaF PET in Active HO Classic ACVR1 Mutation (AHOC) analysis set up to Week 28 is reported.
Time frame: Week 28
Period 1: Percent Change From Baseline in the Total Volume of HO Lesions as Assessed by CT at Week 28 (AHOC)
CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Percent change from baseline in the total volume of HO lesions was assessed by CT at Week 28 in AHOC analysis set is reported.
Time frame: Week 28
Period 1: Time-weighted Average (Standardized AUC) of the Change From Baseline in Daily Pain Due to Fibrodysplasia Ossificans Progressiva (FOP) Assessed by Daily Numeric Rating Scale (NRS) at Week 28 (AHO)
The pain NRS is a patient reported outcome (PRO) used by participants to rate their pain associated with FOP. Participants were asked to rate their pain on a scale that ranges from "0" (no pain) to "10" (worst possible pain), where the highest score indicated worst outcome. Time-weighted average (Standardized AUC) of the change from baseline in daily pain due to FOP assessed by daily NRS at Week 28 in AHO analysis set is reported.
Time frame: Week 28
Period 1: Time-weighted Average (Standardized AUC) of the Change From Baseline in Daily Pain Due to FOP, Assessed by Daily NRS at Week 28 (AHOC)
The pain NRS is a PRO used by participants to rate their pain associated with FOP. Participants were asked to rate their pain on a scale that ranges from "0" (no pain) to "10" (worst possible pain), where the highest score indicated worst outcome. Time-Weighted average (standardized AUC) of the change from baseline in daily pain due to FOP assessed by daily NRS at Week 28 in AHOC analysis set is reported.
Time frame: Week 28
Period 1: Percent Change From Baseline in 18^F-NaF SUVmax of Individual Active HO Site(s) Assessed by 18^F-NaF PET at Week 8 (AHOC)
Standardized uptake value max (SUVmax) was a measurement of the maximum radiopharmaceutical uptake within the volume of interest. Relative accuracy of a particular radiotracer in a particular tissue is determined by expressing the absolute accuracy (obtained in the primary outcome measure) in terms of percent difference between SUVmax values obtained from PET/CT. Percent Change in 18\^F-NaF SUVmax of Individual Active HO Site(s) assessed by 18\^F-NaF PET in AHOC analysis set is reported.
Time frame: Week 8
Period 1: Percent Change From Baseline in 18^F-NaF SUVmax of Individual Active HO Site(s) as Assessed by 18^F-NaFPET at Week 8 (AHO)
Percent change in 18\^F-NaF SUVmax of individual active HO site(s) as assessed by 18\^F-NaF PET at Week 8 in AHO analysis set is reported.
Time frame: Week 8
Period 1: Change From Baseline in Number of HO Lesions as Assessed by 18^F-NaF PET at Week 28 (AHOC)
Change from baseline in number of HO lesions was assessed by 18\^F-NaF PET at Week 28 in AHOC analysis set is reported.
Time frame: Week 28
Period 1: Change From Baseline in Number of HO Lesions as Assessed by 18^F-NaF PET at Week 28 (AHO)
Change from baseline in number of HO lesions was assessed by 18\^F-NaF PET in AHO analysis set is reported.
Time frame: Week 28
Period 1: Change From Baseline in Number of HO Lesions Detectable by CT at Week 28 (AHOC)
CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Change from baseline in number of HO lesions was detectable by CT using AHOC analysis set is reported.
Time frame: Week 28
Period 1: Change From Baseline in Number of HO Lesions Detectable by CT at Week 28 (AHO)
CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Change from baseline in number of HO lesions detectable by CT at Week 28 in AHO analysis set is reported.
Time frame: Week 28
Period 2: Number of New HO Lesions as Assessed by 18^F-NaF PET at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)
Number of new HO lesions as assessed by 18\^F-NaF PET at Week 56 Relative to Week 28 Scan is reported.
Time frame: Week 28, Week 56
Period 2: Percentage of Participants With New HO Lesions as Assessed by CT at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)
CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Percentage of participants with new HO lesions as assessed by CT at week 56 relative to week 28 scan is reported.
Time frame: Week 28, Week 56
Period 2: Percentage of Participants With New HO Lesions as Assessed by 18^F-NaF PET at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)
18\^F-NaF PET is used to assess lesion and disease activity. Percentage of participants with new HO lesions as assessed by 18\^F-NaF PET at week 56 relative to week 28 scan is reported.
Time frame: Week 28, Week 56
Period 2: Number of New HO Lesions as Assessed by CT Only at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)
CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT Only: Computed Tomography (CT) assessment without reference to positron-emission tomography (PET). Number of new HO lesions as assessed by CT only at week 56 relative to week 28 scan is reported.
Time frame: Week 28, Week 56
Period 2: Percentage of Participants With New HO Lesions as Assessed by CT Only at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)
CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT Only: Computed Tomography (CT) assessment without reference to Positron-Emission Tomography (PET). Percentage of participants with new HO lesions as assessed by CT only at week 56 relative to week 28 scan is reported.
Time frame: Week 28, Week 56
Period 2 vs. Period 1: Change From Week 28 in Number of Active HO Lesions as Assessed by 18^F-NaF PET to Week 56 (Period 2) Versus the Same Participants Between Baseline and Week 28 (Period 1) (AHO COVID-19 mITT)
18\^F-NaF PET is used to assess lesion and disease activity. Difference of Change from Week 28 to Week 56 as assessed by 18\^F-NaF PET versus from Baseline to Week 28
Time frame: Week 28, Week 56
Period 2 vs. Period 1: Change From Week 28 in Number of Active HO Lesions as Assessed by CT Scan at Week 56 (Period 2) Versus the Same Participants Between Baseline and Week 28 (Period 1) (AHO COVID-19 mITT)
CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Difference of Change from Week 28 to Week 56 as assessed by CT Scan versus from Baseline to Week 28 is reported
Time frame: Week 28, Week 56
Period 2: Number of New HO Lesions as Assessed by CT at Week 56 Relative to Baseline (AHO COVID-19 mITT)
CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Number of new HO lesions as assessed by CT at week 56 relative to baseline.
Time frame: Baseline, Week 56
Period 2: Number of New HO Lesions as Assessed by CT Only at Week 56 Relative to Baseline (AHO COVID-19 mITT)
CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT Only: Computed Tomography (CT) assessment without reference to Positron-Emission Tomography (PET); Number of new HO lesions as assessed by CT only at week 56 relative baseline is reported.
Time frame: Week 56
Period 2: Percentage of Participants With New HO Lesions as Assessed by CT at Week 56 Relative to Baseline (AHO COVID-19 mITT)
CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Percentage of participants with new HO lesions as assessed by CT at week 56 relative to baseline were reported.
Time frame: Week 56
Period 2: Number of New HO Lesions as Assessed by 18^F-NAF PET at Week 56 Relative to Baseline (AHO COVID-19 mITT)
18\^F-NaF PET is used to assess lesion and disease activity. Number of new HO lesions as assessed by 18\^F-NAF PET at week 56 relative to baseline is reported.
Time frame: Week 56
Period 2: Percentage of Participants With New HO Lesions as Assessed by 18^F-NaF PET at Week 56 Relative to Baseline (AHO COVID-19 mITT)
18\^F-NaF PET is used to assess lesion and disease activity. Percentage of participants with new HO lesions as assessed by 18\^F-NaF PET at week 56 relative to baseline.
Time frame: Week 56
Period 2: Total Volume of New HO Lesions as Assessed by CT at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)
CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Total volume of new HO lesions as assessed by CT at Week 56 relative to Week 28 scan.
Time frame: Week 28, Week 56
Period 2: Total Lesion Activity (TLA) Assessed by 18^F-NaF PET in New HO Lesions at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)
TLA is a measure of participant-level cumulative burden of metabolically active HO. Activity of individual HO lesions was calculated as the product of mean standard uptake value (SUVmean) and the PET volume of the active HO lesion. TLA was derived for each participant at each time point as the sum of HO lesion activity of individual target and new active HO lesions.
Time frame: Week 28, Week 56
Period 2 vs. Period 1: Percent Change From Week 28 in TLA as Assessed by 18^F-NaF PET to Week 56 (Period 2) Versus the Same Participants Between Baseline and Week 28 (Period 1) (AHO COVID-19 mITT)
Difference of Percent Change from Week 28 to Week 56 versus from Baseline to Week 28 is reported
Time frame: Week 28, Week 56
Period 2 vs. Period 1: Percent Change From Week 28 in the Total Volume of HO Lesions as Assessed by CT to Week 56 (Period 2) Versus the Same Participants Between Baseline and Week 28 (Period 1) (AHO COVID-19 mITT)
CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Difference of Percent Change from Week 28 to Week 56 versus from Baseline to Week 28 is reported.
Time frame: Week 28, Week 56
Period 2: TLA in New HO Lesions as Assessed by 18^F-NaF PET at Week 56 Relative to Baseline (AHO COVID-19 mITT)
Total Lesion Activity (TLA) is a measure of participant-level cumulative burden of metabolically active HO. TLA in New (Relative to Baseline) Lesions at Week 56 is reported.
Time frame: Week 56
Period 2: Total Volume of New HO Lesions as Assessed by CT Only at Week 56 Relative to Baseline (AHO COVID-19 mITT)
CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT Only: Computed Tomography (CT) assessment without reference to Positron-Emission Tomography (PET); Total volume of new HO lesions as assessed by CT only at week 56 relative to baseline is reported.
Time frame: Week 56
Period 2: Percent Change From Baseline in TLA as Assessed by 18^F-NaF PET to Week 56 (AHO COVID-19 mITT)
Percent change from baseline in TLA as assessed by 18\^F-NaF PET to week 56 were reported.
Time frame: Week 56
Period 2: Percent Change From Baseline in the Total Volume of HO Lesions as Assessed by CT to Week 56 (AHO COVID-19 mITT)
CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Percent change from baseline in the total volume of HO lesions as assessed by CT to Week 56 were reported.
Time frame: Week 56
Period 2: Percent Change From Week 28 in SUVmax as Assessed by 18^F-NaF to Week 56 (AHO COVID-19 mITT)
Percent Change from Week 28 to Week 56 is reported.
Time frame: Week 28 to Week 56
Period 2: Percent Change From Baseline in 18^F-NaF PET SUVmax to Week 56 (AHO COVID-19 mITT)
Percent change from baseline in 18\^F-NaF PET SUVmax to week 56
Time frame: Baseline, Week 56
Period 2: Daily Average Pain Due to FOP Measured Using the Daily NRS
The pain NRS is a patient reported outcome used by participants to rate their pain associated with FOP. Participants were asked to rate their pain on a scale that ranges from "0" (no pain) to "10" (worst possible pain), where the highest score indicated worst outcome.
Time frame: Week 28 up to Week 56
Period 2: Percentage of Participants With Flare-ups Assessed by Participant E-diary
Percentage of participants with flare-ups starting between week 28 and week 56 as assessed by participant E-diary is reported.
Time frame: Week 28 to Week 56
Period 2: Percentage of Participants With Investigator-assessed Flare-ups
Percentage of participants with investigator-assessed flare-ups were reported.
Time frame: Week 28 to Week 56
Periods 1, 2, and 3: Concentration of Total Activin A in Serum
Concentration of total activin A in serum over time is reported.
Time frame: Week 28, Week 56, Week 76
Periods 1, 2, and 3: Concentrations of Functional REGN2477 in Serum
Concentrations of REGN2477 capable of target binding were measured (functional drug).
Time frame: Week 28, Week 56, Week 76
Periods 1, 2, and 3: Number of Participants With Clinical Impact of Treatment-Emergent Anti-drug Antibodies (ADA) to REGN2477
Immunogenicity was characterized by ADA responses \& titers. Responses categories: Negative - ADA negative response at all time points, regardless of missing samples; Pre-existing immunoreactivity - ADA positive response at baseline with all post first dose negative results or positive response at baseline with all post first dose ADA responses \< 9-fold over baseline titer levels; Treatment-boosted response - positive response in the assay post first dose, \>= 9-fold over baseline titer levels, when baseline results are positive; Treatment-emergent response - ADA positive response in the REGN2477 ADA assay post first dose when baseline results = negative or missing.
Time frame: Up to Week 76
A total of 48 participants were screened, out of which, 44 participants were randomized and treated.
| Milestone | Placebo | REGN2477 10 mg/kg Q4W | Placebo/REGN2477 10 mg/kg Q4W | REGN2477/REGN2477 10 mg/kg Q4W |
|---|---|---|---|---|
| Started | 24 | 20 | 0 | 0 |
| Completed | 24 | 19 | 0 | 0 |
| Not completed | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Milestone | Placebo | REGN2477 10 mg/kg Q4W | Placebo/REGN2477 10 mg/kg Q4W | REGN2477/REGN2477 10 mg/kg Q4W |
|---|---|---|---|---|
| Started | 0 | 0 | 24 | 19 |
| Completed | 0 | 0 | 24 | 18 |
| Not completed | 0 | 0 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 0 | 1 |
| Milestone | Placebo | REGN2477 10 mg/kg Q4W | Placebo/REGN2477 10 mg/kg Q4W | REGN2477/REGN2477 10 mg/kg Q4W |
|---|---|---|---|---|
| Started | 0 | 0 | 24 | 18 |
| Completed | 0 | 0 | 21 | 16 |
| Not completed | 0 | 0 | 3 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 | 0 |
| Withdrew: Death | 0 | 0 | 1 | 2 |
Treatment-emergent adverse events (TEAEs) are adverse events not present at baseline or represent the exacerbation of a pre-existing condition during the on-treatment period. A serious TEAE was defined as any untoward medical occurrence that resulted in any of following outcomes not present at baseline or represent the exacerbation of a pre-existing condition during the on-treatment period: death, life-threatening, required initial/prolonged in-participant hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect/considered as medically important event. Number of participants with TEAEs and Serious TEAEs are reported.
| Participants | Placebo | REGN2477 10 mg/kg Q4W |
|---|---|---|
| Participants with at least one TEAE | 24 | 20 |
| Participants with at least one serious TEAE | 2 | 4 |
Severity of TEAEs were graded as follows: Mild: Does not interfere in a significant manner with the participant's normal functioning level. It may be an annoyance. Prescription drugs are not ordinarily needed for relief of symptoms but may be given because of personality of the participants. Moderate: Produces some impairment of functioning but is not hazardous to health. It was uncomfortable or an embarrassment. Treatment for symptom may be needed. Severe: Produces significant impairment of functioning or incapacitation and was a definite hazard to the participant's health. Treatment for symptom may be given and/or participants hospitalized. Number of participants with TEAEs by severity is reported.
| Participants | Placebo | REGN2477 10 mg/kg Q4W |
|---|---|---|
| Participants with at least one Mild TEAE | 9 | 7 |
| Participants with at least one Moderate TEAE | 12 | 10 |
| Participants with at least one Severe TEAE | 3 | 3 |
18\^F-NaF PET is used to assess lesion and disease activity. Time-weighted average (standardized area under the curve \[AUC\]) of the percent change from baseline in total lesion activity by 18\^F-NaF PET up to Week 28 in AHO analysis set is reported.
| Percent Change | Placebo | REGN2477 10 mg/kg Q4W |
|---|---|---|
| Period 1: Time-Weighted Average (Standardized Area Under the Curve [AUC]) of the Percent Change From Baseline in Total Lesion Activity by Fluorine-18-labeled Sodium Fluoride (18^F-NaF) Positron Emission Tomography (PET) at Week 28 (AHO) | 16.6 ± 9.11 | -8.1 ± 9.93 |
CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Percent change from baseline in the total volume of HO lesions as assessed by CT during Period 1 at Week 28 is reported.
| Percent Change | Placebo | REGN2477 10 mg/kg Q4W |
|---|---|---|
| Period 1: Percent Change From Baseline in the Total Volume of HO Lesions as Assessed by Computed Tomography (CT) at Week 28 (AHO) | 32.0 ± 18.66 | 7.1 ± 20.43 |
CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. HO detectable by CT that developed after baseline are referred to as "new HO lesions." Number of new HO lesions as assessed by CT at Week 56 relative to Week 28 scan is reported.
| New HO Lesions | Placebo/REGN2477 10 mg/kg Q4W |
|---|---|
| Period 2: Number of New HO Lesions as Assessed by CT at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT) | 0 |
18\^F-NaF PET is used to assess lesion and disease activity. Time-weighted average (Standardized AUC) of the percent change from baseline in total lesion activity as assessed by 18\^F-NaF PET in Active HO Classic ACVR1 Mutation (AHOC) analysis set up to Week 28 is reported.
| Percent Change | Placebo | REGN2477 10 mg/kg Q4W |
|---|---|---|
| Period 1: Time-weighted Average (Standardized AUC) of the Percent Change From Baseline in Total Lesion Activity Assessed by 18^F-NaF PET at Week 28 (AHOC) | 17.6 ± 9.73 | -8.0 ± 10.14 |
CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Percent change from baseline in the total volume of HO lesions was assessed by CT at Week 28 in AHOC analysis set is reported.
| Percent Change | Placebo | REGN2477 10 mg/kg Q4W |
|---|---|---|
| Period 1: Percent Change From Baseline in the Total Volume of HO Lesions as Assessed by CT at Week 28 (AHOC) | 34.9 ± 19.90 | 7.0 ± 20.87 |
The pain NRS is a patient reported outcome (PRO) used by participants to rate their pain associated with FOP. Participants were asked to rate their pain on a scale that ranges from "0" (no pain) to "10" (worst possible pain), where the highest score indicated worst outcome. Time-weighted average (Standardized AUC) of the change from baseline in daily pain due to FOP assessed by daily NRS at Week 28 in AHO analysis set is reported.
| Score on a Scale | Placebo | REGN2477 10 mg/kg Q4W |
|---|---|---|
| Period 1: Time-weighted Average (Standardized AUC) of the Change From Baseline in Daily Pain Due to Fibrodysplasia Ossificans Progressiva (FOP) Assessed by Daily Numeric Rating Scale (NRS) at Week 28 (AHO) | -0.17 ± 0.205 | -0.51 ± 0.231 |
The pain NRS is a PRO used by participants to rate their pain associated with FOP. Participants were asked to rate their pain on a scale that ranges from "0" (no pain) to "10" (worst possible pain), where the highest score indicated worst outcome. Time-Weighted average (standardized AUC) of the change from baseline in daily pain due to FOP assessed by daily NRS at Week 28 in AHOC analysis set is reported.
| Score on a Scale | Placebo | REGN2477 10 mg/kg Q4W |
|---|---|---|
| Period 1: Time-weighted Average (Standardized AUC) of the Change From Baseline in Daily Pain Due to FOP, Assessed by Daily NRS at Week 28 (AHOC) | -0.12 ± 0.221 | -0.48 ± 0.237 |
Standardized uptake value max (SUVmax) was a measurement of the maximum radiopharmaceutical uptake within the volume of interest. Relative accuracy of a particular radiotracer in a particular tissue is determined by expressing the absolute accuracy (obtained in the primary outcome measure) in terms of percent difference between SUVmax values obtained from PET/CT. Percent Change in 18\^F-NaF SUVmax of Individual Active HO Site(s) assessed by 18\^F-NaF PET in AHOC analysis set is reported.
| Percent Change | Placebo | REGN2477 10 mg/kg Q4W |
|---|---|---|
| Period 1: Percent Change From Baseline in 18^F-NaF SUVmax of Individual Active HO Site(s) Assessed by 18^F-NaF PET at Week 8 (AHOC) | -6.7 ± 28.79 | -21.6 ± 30.25 |
Percent change in 18\^F-NaF SUVmax of individual active HO site(s) as assessed by 18\^F-NaF PET at Week 8 in AHO analysis set is reported.
| Percent Change | Placebo | REGN2477 10 mg/kg Q4W |
|---|---|---|
| Period 1: Percent Change From Baseline in 18^F-NaF SUVmax of Individual Active HO Site(s) as Assessed by 18^F-NaFPET at Week 8 (AHO) | -7.9 ± 28.80 | -21.6 ± 30.25 |
Change from baseline in number of HO lesions was assessed by 18\^F-NaF PET at Week 28 in AHOC analysis set is reported.
| HO Lesions | Placebo | REGN2477 10 mg/kg Q4W |
|---|---|---|
| Period 1: Change From Baseline in Number of HO Lesions as Assessed by 18^F-NaF PET at Week 28 (AHOC) | -1.0 ± 2.66 | -2.3 ± 2.24 |
Change from baseline in number of HO lesions was assessed by 18\^F-NaF PET in AHO analysis set is reported.
| HO Lesions | Placebo | REGN2477 10 mg/kg Q4W |
|---|---|---|
| Period 1: Change From Baseline in Number of HO Lesions as Assessed by 18^F-NaF PET at Week 28 (AHO) | -1.0 ± 2.59 | -2.3 ± 2.24 |
CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Change from baseline in number of HO lesions was detectable by CT using AHOC analysis set is reported.
| HO Lesions | Placebo | REGN2477 10 mg/kg Q4W |
|---|---|---|
| Period 1: Change From Baseline in Number of HO Lesions Detectable by CT at Week 28 (AHOC) | 1.2 ± 2.00 | -0.3 ± 1.34 |
CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Change from baseline in number of HO lesions detectable by CT at Week 28 in AHO analysis set is reported.
| HO Lesions | Placebo | REGN2477 10 mg/kg Q4W |
|---|---|---|
| Period 1: Change From Baseline in Number of HO Lesions Detectable by CT at Week 28 (AHO) | 1.2 ± 1.93 | -0.3 ± 1.34 |
Number of new HO lesions as assessed by 18\^F-NaF PET at Week 56 Relative to Week 28 Scan is reported.
| New HO lesions | Placebo/REGN2477 10 mg/kg Q4W |
|---|---|
| Period 2: Number of New HO Lesions as Assessed by 18^F-NaF PET at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT) | 1 |
CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Percentage of participants with new HO lesions as assessed by CT at week 56 relative to week 28 scan is reported.
| Percentage of Participants | Placebo/REGN2477 10 mg/kg Q4W |
|---|---|
| Period 2: Percentage of Participants With New HO Lesions as Assessed by CT at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT) | 0.0 |
18\^F-NaF PET is used to assess lesion and disease activity. Percentage of participants with new HO lesions as assessed by 18\^F-NaF PET at week 56 relative to week 28 scan is reported.
| Percentage of Participants | Placebo/REGN2477 10 mg/kg Q4W |
|---|---|
| Period 2: Percentage of Participants With New HO Lesions as Assessed by 18^F-NaF PET at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT) | 4.5 |
CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT Only: Computed Tomography (CT) assessment without reference to positron-emission tomography (PET). Number of new HO lesions as assessed by CT only at week 56 relative to week 28 scan is reported.
| New HO lesions | Placebo/REGN2477 10 mg/kg Q4W |
|---|---|
| Period 2: Number of New HO Lesions as Assessed by CT Only at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT) | 3 |
CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT Only: Computed Tomography (CT) assessment without reference to Positron-Emission Tomography (PET). Percentage of participants with new HO lesions as assessed by CT only at week 56 relative to week 28 scan is reported.
| Percentage of Participants | Placebo/REGN2477 10 mg/kg Q4W |
|---|---|
| Period 2: Percentage of Participants With New HO Lesions as Assessed by CT Only at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT) | 9.1 |
18\^F-NaF PET is used to assess lesion and disease activity. Difference of Change from Week 28 to Week 56 as assessed by 18\^F-NaF PET versus from Baseline to Week 28
| Active lesions | Placebo/REGN2477 10 mg/kg Q4W | REGN2477/REGN2477 10 mg/kg Q4W |
|---|---|---|
| Period 2 vs. Period 1: Change From Week 28 in Number of Active HO Lesions as Assessed by 18^F-NaF PET to Week 56 (Period 2) Versus the Same Participants Between Baseline and Week 28 (Period 1) (AHO COVID-19 mITT) | -1.2 ± 4.31 | 1.3 ± 3.26 |
CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Difference of Change from Week 28 to Week 56 as assessed by CT Scan versus from Baseline to Week 28 is reported
| Active lesions | Placebo/REGN2477 10 mg/kg Q4W | REGN2477/REGN2477 10 mg/kg Q4W |
|---|---|---|
| Period 2 vs. Period 1: Change From Week 28 in Number of Active HO Lesions as Assessed by CT Scan at Week 56 (Period 2) Versus the Same Participants Between Baseline and Week 28 (Period 1) (AHO COVID-19 mITT) | -1.3 ± 2.40 | 0.3 ± 1.24 |
CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Number of new HO lesions as assessed by CT at week 56 relative to baseline.
| New HO Lesions | REGN2477/REGN2477 10 mg/kg Q4W |
|---|---|
| Period 2: Number of New HO Lesions as Assessed by CT at Week 56 Relative to Baseline (AHO COVID-19 mITT) | 2 |
CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT Only: Computed Tomography (CT) assessment without reference to Positron-Emission Tomography (PET); Number of new HO lesions as assessed by CT only at week 56 relative baseline is reported.
| New HO Lesions | REGN2477/REGN2477 10 mg/kg Q4W |
|---|---|
| Period 2: Number of New HO Lesions as Assessed by CT Only at Week 56 Relative to Baseline (AHO COVID-19 mITT) | 1 |
CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Percentage of participants with new HO lesions as assessed by CT at week 56 relative to baseline were reported.
| Percentage of Participants | REGN2477/REGN2477 10 mg/kg Q4W |
|---|---|
| Period 2: Percentage of Participants With New HO Lesions as Assessed by CT at Week 56 Relative to Baseline (AHO COVID-19 mITT) | 11.1 |
18\^F-NaF PET is used to assess lesion and disease activity. Number of new HO lesions as assessed by 18\^F-NAF PET at week 56 relative to baseline is reported.
| New HO Lesions | REGN2477/REGN2477 10 mg/kg Q4W |
|---|---|
| Period 2: Number of New HO Lesions as Assessed by 18^F-NAF PET at Week 56 Relative to Baseline (AHO COVID-19 mITT) | 1 |
18\^F-NaF PET is used to assess lesion and disease activity. Percentage of participants with new HO lesions as assessed by 18\^F-NaF PET at week 56 relative to baseline.
| Percentage of Participants | REGN2477/REGN2477 10 mg/kg Q4W |
|---|---|
| Period 2: Percentage of Participants With New HO Lesions as Assessed by 18^F-NaF PET at Week 56 Relative to Baseline (AHO COVID-19 mITT) | 5.6 |
CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Total volume of new HO lesions as assessed by CT at Week 56 relative to Week 28 scan.
| cubic centimeter (cm^3) | Placebo/REGN2477 10 mg/kg Q4W |
|---|---|
| Period 2: Total Volume of New HO Lesions as Assessed by CT at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT) | 0.0 ± 0.21 |
TLA is a measure of participant-level cumulative burden of metabolically active HO. Activity of individual HO lesions was calculated as the product of mean standard uptake value (SUVmean) and the PET volume of the active HO lesion. TLA was derived for each participant at each time point as the sum of HO lesion activity of individual target and new active HO lesions.
| gram (g) | Placebo/REGN2477 10 mg/kg Q4W |
|---|---|
| Period 2: Total Lesion Activity (TLA) Assessed by 18^F-NaF PET in New HO Lesions at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT) | 13.2 ± 61.89 |
Difference of Percent Change from Week 28 to Week 56 versus from Baseline to Week 28 is reported
| Percent Change | Placebo/REGN2477 10 mg/kg Q4W | REGN2477/REGN2477 10 mg/kg Q4W |
|---|---|---|
| Period 2 vs. Period 1: Percent Change From Week 28 in TLA as Assessed by 18^F-NaF PET to Week 56 (Period 2) Versus the Same Participants Between Baseline and Week 28 (Period 1) (AHO COVID-19 mITT) | -66.9 ± 181.06 | 14.0 ± 41.17 |
CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Difference of Percent Change from Week 28 to Week 56 versus from Baseline to Week 28 is reported.
| Percent Change | Placebo/REGN2477 10 mg/kg Q4W | REGN2477/REGN2477 10 mg/kg Q4W |
|---|---|---|
| Period 2 vs. Period 1: Percent Change From Week 28 in the Total Volume of HO Lesions as Assessed by CT to Week 56 (Period 2) Versus the Same Participants Between Baseline and Week 28 (Period 1) (AHO COVID-19 mITT) | -31.8 ± 132.47 | -11.1 ± 24.07 |
Total Lesion Activity (TLA) is a measure of participant-level cumulative burden of metabolically active HO. TLA in New (Relative to Baseline) Lesions at Week 56 is reported.
| gram (g) | REGN2477/ REGN2477 |
|---|---|
| Period 2: TLA in New HO Lesions as Assessed by 18^F-NaF PET at Week 56 Relative to Baseline (AHO COVID-19 mITT) | 0.7 ± 2.13 |
CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT Only: Computed Tomography (CT) assessment without reference to Positron-Emission Tomography (PET); Total volume of new HO lesions as assessed by CT only at week 56 relative to baseline is reported.
| cubic centimeter (cm^3) | REGN2477/REGN2477 10 mg/kg Q4W |
|---|---|
| Period 2: Total Volume of New HO Lesions as Assessed by CT Only at Week 56 Relative to Baseline (AHO COVID-19 mITT) | 0.0 ± 0.02 |
Percent change from baseline in TLA as assessed by 18\^F-NaF PET to week 56 were reported.
| Percent Change | REGN2477/REGN2477 10 mg/kg Q4W |
|---|---|
| Period 2: Percent Change From Baseline in TLA as Assessed by 18^F-NaF PET to Week 56 (AHO COVID-19 mITT) | -16.4 ± 53.10 |
CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Percent change from baseline in the total volume of HO lesions as assessed by CT to Week 56 were reported.
| Percent Change | REGN2477/REGN2477 10 mg/kg Q4W |
|---|---|
| Period 2: Percent Change From Baseline in the Total Volume of HO Lesions as Assessed by CT to Week 56 (AHO COVID-19 mITT) | 2.6 ± 10.18 |
Percent Change from Week 28 to Week 56 is reported.
| Percent Change | Placebo/REGN2477 10 mg/kg Q4W |
|---|---|
| Period 2: Percent Change From Week 28 in SUVmax as Assessed by 18^F-NaF to Week 56 (AHO COVID-19 mITT) | -30.3 ± 15.03 |
Percent change from baseline in 18\^F-NaF PET SUVmax to week 56
| Percent Change | REGN2477/REGN2477 10 mg/kg Q4W |
|---|---|
| Period 2: Percent Change From Baseline in 18^F-NaF PET SUVmax to Week 56 (AHO COVID-19 mITT) | -41.9 ± 29.16 |
The pain NRS is a patient reported outcome used by participants to rate their pain associated with FOP. Participants were asked to rate their pain on a scale that ranges from "0" (no pain) to "10" (worst possible pain), where the highest score indicated worst outcome.
| Score on a Scale | Placebo/REGN2477 10 mg/kg Q4W |
|---|---|
| Period 2: Daily Average Pain Due to FOP Measured Using the Daily NRS | 1.60 ± 1.969 |
Percentage of participants with flare-ups starting between week 28 and week 56 as assessed by participant E-diary is reported.
| Percentage of Participants | Placebo/REGN2477 10 mg/kg Q4W |
|---|---|
| Period 2: Percentage of Participants With Flare-ups Assessed by Participant E-diary | 13.6 |
Percentage of participants with investigator-assessed flare-ups were reported.
| Percentage of Participants | Placebo/REGN2477 10 mg/kg Q4W |
|---|---|
| Period 2: Percentage of Participants With Investigator-assessed Flare-ups | 13.6 |
Concentration of total activin A in serum over time is reported.
| milligram per Liter (mg/L) | Placebo/REGN2477 10 mg/kg Q4W | REGN2477/REGN2477 10 mg/kg Q4W |
|---|---|---|
| Week 28 | 0.0000813 ± 0.000164 | 0.0537 ± 0.0116 |
| Week 56 | 0.0563 ± 0.0172 | 0.0503 ± 0.0113 |
| Week 76 | 0.0487 ± 0.0192 | 0.0497 ± 0.0176 |
Concentrations of REGN2477 capable of target binding were measured (functional drug).
| mg/L | Placebo/REGN2477 10 mg/kg Q4W | REGN2477 10 mg/kg Q4W |
|---|---|---|
| Week 28 | 0 ± 0 | 130 ± 46.6 |
| Week 56 | 100 ± 27.3 | 122 ± 54.8 |
| Week 76 | 113 ± 27.0 | 113 ± 23.0 |
Immunogenicity was characterized by ADA responses \& titers. Responses categories: Negative - ADA negative response at all time points, regardless of missing samples; Pre-existing immunoreactivity - ADA positive response at baseline with all post first dose negative results or positive response at baseline with all post first dose ADA responses \< 9-fold over baseline titer levels; Treatment-boosted response - positive response in the assay post first dose, \>= 9-fold over baseline titer levels, when baseline results are positive; Treatment-emergent response - ADA positive response in the REGN2477 ADA assay post first dose when baseline results = negative or missing.
| Participants | Placebo/REGN2477 10 mg/kg Q4W | REGN2477/ REGN2477 |
|---|---|---|
| Negative | 24 | 18 |
| Pre-existing Immunoreactivity | 0 | 0 |
| Treatment-Boosted Response | 0 | 0 |
| Treatment-Emergent Response | 0 | 1 |
Collected over From first dose of study drug to end of study. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/24 (0%) | 2/24 (8.3%) | 24/24 (100%) |
| REGN2477 10 mg/kg Q4W | 0/20 (0%) | 4/20 (20%) | 20/20 (100%) |
| Placebo/REGN2477 10 mg/kg Q4W | 2/24 (8.3%) | 6/24 (25%) | 24/24 (100%) |
| REGN2477/REGN2477 10 mg/kg Q4W | 3/19 (15.8%) | 7/19 (36.8%) | 18/19 (94.7%) |
| Event | Placebo | REGN2477 10 mg/kg Q4W | Placebo/REGN2477 10 mg/kg Q4W | REGN2477/REGN2477 10 mg/kg Q4W |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/24 | 1/20 | 0/24 | 1/19 |
| AbscessInfections and infestations | 0/24 | 0/20 | 0/24 | 1/19 |
| Perirectal abscessInfections and infestations | 0/24 | 0/20 | 0/24 | 1/19 |
| Respiratory tract infection viralInfections and infestations | 0/24 | 0/20 | 0/24 | 1/19 |
| Subcutaneous abscessInfections and infestations | 0/24 | 0/20 | 0/24 | 1/19 |
| Intestinal obstructionGastrointestinal disorders | 0/24 | 1/20 | 0/24 | 1/19 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/24 | 0/20 | 0/24 | 1/19 |
| PyrexiaGeneral disorders | 0/24 | 0/20 | 1/24 | 1/19 |
| Head injuryInjury, poisoning and procedural complications | 0/24 | 0/20 | 0/24 | 1/19 |
| Cerebrovascular accidentNervous system disorders | 0/24 | 0/20 | 0/24 | 1/19 |
| Event | Placebo | REGN2477 10 mg/kg Q4W | Placebo/REGN2477 10 mg/kg Q4W | REGN2477/REGN2477 10 mg/kg Q4W |
|---|---|---|---|---|
| MadarosisSkin and subcutaneous tissue disorders | 0/24 | 6/20 | 13/24 | 8/19 |
| HeadacheNervous system disorders | 7/24 | 10/20 | 6/24 | 8/19 |
| AcneSkin and subcutaneous tissue disorders | 3/24 | 6/20 | 12/24 | 4/19 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 4/24 | 10/20 | 10/24 | 5/19 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 9/24 | 7/20 | 8/24 | 9/19 |
| NasopharyngitisInfections and infestations | 5/24 | 3/20 | 5/24 | 9/19 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 9/24 | 5/20 | 6/24 | 8/19 |
| PyrexiaGeneral disorders | 0/24 | 3/20 | 5/24 | 7/19 |
| Back painMusculoskeletal and connective tissue disorders | 1/24 | 4/20 | 7/24 | 6/19 |
| DiarrhoeaGastrointestinal disorders | 6/24 | 5/20 | 5/24 | 2/19 |
The full analysis set (FAS) included all randomized participants and was based on the treatment allocated.
| Age, Continuous(Years) | Placebo | REGN2477 10 mg/kg Q4W | Total |
|---|---|---|---|
| Mean | 27.8 ± 8.54 | 27.3 ± 8.67 | 27.6 ± 8.50 |
| Sex: Female, Male(Participants) | Placebo | REGN2477 10 mg/kg Q4W | Total |
|---|---|---|---|
| Female | 14 | 11 | 25 |
| Male | 10 | 9 | 19 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | REGN2477 10 mg/kg Q4W | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 24 | 20 | 44 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | REGN2477 10 mg/kg Q4W | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 2 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 22 | 17 | 39 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Total Lesion Activity by fluorine-18 sodium fluoride (18 F-NaF) PET (AHO Analysis Set)(gram (g)) | Placebo | REGN2477 10 mg/kg Q4W | Total |
|---|---|---|---|
| Mean | 473.40 ± 348.373 | 418.18 ± 372.801 | 448.30 ± 356.510 |
| Total Volume of HO Lesions as Assessed by Computed Tomography (CT) (AHO Analysis Set)(cubic centimeter (cm^3)) | Placebo | REGN2477 10 mg/kg Q4W | Total |
|---|---|---|---|
| Mean | 235.78 ± 253.329 | 251.43 ± 327.881 | 242.89 ± 286.167 |
| Total Lesion Activity by 18F-NaF PET (AHOC Analysis Set)(gram (g)) | Placebo | REGN2477 10 mg/kg Q4W | Total |
|---|---|---|---|
| Mean | 464.27 ± 350.479 | 418.18 ± 372.801 | 442.32 ± 357.581 |
| Total Volume of HO Lesions as Assessed by CT (AHOC Analysis Set)(cubic centimeter (cm^3)) | Placebo | REGN2477 10 mg/kg Q4W | Total |
|---|---|---|---|
| Mean | 239.72 ± 263.813 | 251.43 ± 327.881 | 245.29 ± 292.408 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2018 to primary completion in Sep 2019, 18 months.
Results were first posted in Dec 2022, 3 years 2 months after primary completion. A results delay was requested in Sep 2020.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Garetosmab